BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2808189)

  • 1. In-vitro synergistic activity between ethambutol and fluorinated quinolones against Mycobacterium avium complex.
    Hoffner SE; Kratz M; Olsson-Liljequist B; Svenson SB; Källenius G
    J Antimicrob Chemother; 1989 Sep; 24(3):317-24. PubMed ID: 2808189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin.
    Yajko DM; Sanders CA; Nassos PS; Hadley WK
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2442-4. PubMed ID: 2088204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.
    Bermudez LE; Inderlied CB; Kolonoski P; Wu M; Barbara-Burnham L; Young LS
    Antimicrob Agents Chemother; 1996 Mar; 40(3):546-51. PubMed ID: 8851568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro evaluation of clarithromycin, temafloxacin, and ethambutol in combination against Mycobacterium avium complex.
    Gevaudan MJ; Bollet C; Mallet MN; de Micco P
    J Antimicrob Chemother; 1993 May; 31(5):725-30. PubMed ID: 8392998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
    Bermudez LE; Inderlied CB; Kolonoski P; Petrofsky M; Aralar P; Wu M; Young LS
    Antimicrob Agents Chemother; 2001 Jan; 45(1):217-22. PubMed ID: 11120969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in-vitro activity of Bay y 3118, a new quinolone, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
    Sirgel FA; Venter A; Heilmann HD
    J Antimicrob Chemother; 1995 Feb; 35(2):349-51. PubMed ID: 7759400
    [No Abstract]   [Full Text] [Related]  

  • 7. [Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi].
    Gevaudan MJ; Bollet C; Mallet MN; de Lamballerie X; Sambuc R; de Micco P
    Pathol Biol (Paris); 1992 May; 40(5):443-9. PubMed ID: 1323093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.
    Rastogi N; Goh KS; Bryskier A; Devallois A
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2483-7. PubMed ID: 8913450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
    Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
    J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electron microscopic analysis of Mycobacterium avium complex isolates exposed to ciprofloxacin, rifabutin, ethambutol and clarithromycin.
    Reisner BS; Woods GL; Popov VL
    Int J Tuberc Lung Dis; 1997 Jun; 1(3):270-5. PubMed ID: 9432376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages.
    Pellegrin I; Maugein J; Lapeyre C; Barbeau P; Leng B; Pellegrin JL
    J Antimicrob Chemother; 1996 Mar; 37(3):501-10. PubMed ID: 9182107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro determination of the sensitivity of mycobacteria to fluoroquinolones].
    Dailloux M; Petitpain N; Henry C; Weber M
    Pathol Biol (Paris); 1989 May; 37(5):346-9. PubMed ID: 2780092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex.
    Rastogi N; Goh KS; Bryskier A
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1433-8. PubMed ID: 8092850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of Mycobacterium avium and Mycobacterium intracellulare to various antibacterial drugs.
    Tomioka H; Sato K; Saito H; Yamada Y
    Microbiol Immunol; 1989; 33(6):509-14. PubMed ID: 2770562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
    Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
    Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of patients with bacteraemia caused by Mycobacterium avium complex species and antimicrobial susceptibility of the isolates at a medical centre in Taiwan, 2008-2014.
    Lee MR; Chien JY; Huang YT; Liao CH; Shu CC; Yu CJ; Hsueh PR
    Int J Antimicrob Agents; 2017 Jul; 50(1):35-40. PubMed ID: 28478210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.
    Klopman G; Fercu D; Renau TE; Jacobs MR
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2637-43. PubMed ID: 8913479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method.
    Tomioka H; Saito H; Fujii K; Sato K; Hidaka T
    Antimicrob Agents Chemother; 1993 Jan; 37(1):67-70. PubMed ID: 8431020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination.
    Bakker-Woudenberg IA; van Vianen W; van Soolingen D; Verbrugh HA; van Agtmael MA
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2387-98. PubMed ID: 15917538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antimycobacterial activity between ethambutol and the beta-lactam drug cefepime.
    Abate G; Hoffner SE
    Diagn Microbiol Infect Dis; 1997 Jul; 28(3):119-22. PubMed ID: 9294701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.